(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...
Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback